Protara Therapeutics, Inc. — Director's Dealing 2017

Jun 21, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2017-06-20

Reporting Person: Freund John Gordon (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-20	Stock Option (Right to Buy)	$1.30	A	6666	Acquired	2027-06-19	Common Stock, $0.001 par value (6666)	Direct

Footnotes

F1: The options were granted on June 20, 2017 and the shares underlying this option will vest 100% at the earlier of (i) June 20, 2018 and (ii) the Issuer's next annual meeting of stockholders.